KR20040027829A - Nano liposome composition for herbs - Google Patents
Nano liposome composition for herbs Download PDFInfo
- Publication number
- KR20040027829A KR20040027829A KR1020040016334A KR20040016334A KR20040027829A KR 20040027829 A KR20040027829 A KR 20040027829A KR 1020040016334 A KR1020040016334 A KR 1020040016334A KR 20040016334 A KR20040016334 A KR 20040016334A KR 20040027829 A KR20040027829 A KR 20040027829A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- composition
- lecithin
- total amount
- composition according
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 80
- 239000002502 liposome Substances 0.000 title claims abstract description 75
- 235000008216 herbs Nutrition 0.000 title 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 53
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 32
- 239000002253 acid Substances 0.000 claims abstract description 21
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims abstract description 19
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims abstract description 19
- 229940106189 ceramide Drugs 0.000 claims abstract description 19
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims abstract description 19
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims abstract description 19
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 15
- 229930182558 Sterol Natural products 0.000 claims abstract description 11
- 150000003432 sterols Chemical class 0.000 claims abstract description 11
- 235000003702 sterols Nutrition 0.000 claims abstract description 11
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims abstract description 5
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 claims abstract description 5
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 claims abstract description 3
- XUGISPSHIFXEHZ-UHFFFAOYSA-N 3beta-acetoxy-cholest-5-ene Natural products C1C=C2CC(OC(C)=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 XUGISPSHIFXEHZ-UHFFFAOYSA-N 0.000 claims abstract description 3
- YEYCQJVCAMFWCO-UHFFFAOYSA-N 3beta-cholesteryl formate Natural products C1C=C2CC(OC=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 YEYCQJVCAMFWCO-UHFFFAOYSA-N 0.000 claims abstract description 3
- JBBRZDLNVILTDL-XNTGVSEISA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] 16-methylheptadecanoate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCCCCCC(C)C)C1 JBBRZDLNVILTDL-XNTGVSEISA-N 0.000 claims abstract description 3
- XUGISPSHIFXEHZ-VEVYEIKRSA-N cholesteryl acetate Chemical compound C1C=C2C[C@@H](OC(C)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 XUGISPSHIFXEHZ-VEVYEIKRSA-N 0.000 claims abstract description 3
- 229940073724 cholesteryl isostearate Drugs 0.000 claims abstract description 3
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229940096998 ursolic acid Drugs 0.000 claims abstract description 3
- 150000003675 ursolic acids Chemical class 0.000 claims abstract description 3
- 239000000284 extract Substances 0.000 claims description 27
- 239000000787 lecithin Substances 0.000 claims description 21
- 235000010445 lecithin Nutrition 0.000 claims description 21
- 229940067606 lecithin Drugs 0.000 claims description 21
- 229940109529 pomegranate extract Drugs 0.000 claims description 11
- 229940069445 licorice extract Drugs 0.000 claims description 9
- 244000146462 Centella asiatica Species 0.000 claims description 8
- 235000004032 Centella asiatica Nutrition 0.000 claims description 8
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims description 8
- 235000008696 isoflavones Nutrition 0.000 claims description 8
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 6
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 6
- 235000021283 resveratrol Nutrition 0.000 claims description 6
- 229940016667 resveratrol Drugs 0.000 claims description 6
- 235000020748 rosemary extract Nutrition 0.000 claims description 6
- 229940092258 rosemary extract Drugs 0.000 claims description 6
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 claims description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 5
- 230000006872 improvement Effects 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 102000008186 Collagen Human genes 0.000 claims description 4
- 108010035532 Collagen Proteins 0.000 claims description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 4
- 229920001436 collagen Polymers 0.000 claims description 4
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 claims description 4
- 235000005152 nicotinamide Nutrition 0.000 claims description 4
- 229960003966 nicotinamide Drugs 0.000 claims description 4
- 239000011570 nicotinamide Substances 0.000 claims description 4
- OWVLYQRCCIEOPF-QHTZZOMLSA-L zinc;(2s)-5-oxopyrrolidine-2-carboxylate Chemical compound [Zn+2].[O-]C(=O)[C@@H]1CCC(=O)N1.[O-]C(=O)[C@@H]1CCC(=O)N1 OWVLYQRCCIEOPF-QHTZZOMLSA-L 0.000 claims description 4
- 229940087603 grape seed extract Drugs 0.000 claims description 3
- 235000002532 grape seed extract Nutrition 0.000 claims description 3
- 235000020688 green tea extract Nutrition 0.000 claims description 3
- 229940094952 green tea extract Drugs 0.000 claims description 3
- 239000001717 vitis vinifera seed extract Substances 0.000 claims description 3
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 2
- 241000906543 Actaea racemosa Species 0.000 claims description 2
- 241001288870 Angelica polymorpha Species 0.000 claims description 2
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 claims description 2
- 235000017647 Brassica oleracea var italica Nutrition 0.000 claims description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 239000006000 Garlic extract Substances 0.000 claims description 2
- 239000009429 Ginkgo biloba extract Substances 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 241000219780 Pueraria Species 0.000 claims description 2
- 241000218206 Ranunculus Species 0.000 claims description 2
- 241000519989 Scutellaria galericulata Species 0.000 claims description 2
- 241000219793 Trifolium Species 0.000 claims description 2
- 206010000496 acne Diseases 0.000 claims description 2
- 229960005305 adenosine Drugs 0.000 claims description 2
- 229940069521 aloe extract Drugs 0.000 claims description 2
- 230000000845 anti-microbial effect Effects 0.000 claims description 2
- 229960000271 arbutin Drugs 0.000 claims description 2
- 235000005301 cimicifuga racemosa Nutrition 0.000 claims description 2
- 235000020706 garlic extract Nutrition 0.000 claims description 2
- LBQIJVLKGVZRIW-UHFFFAOYSA-N glabridine Natural products C1OC2=C3C=CC(C)(C)OC3=CC=C2CC1C1=CC=C(O)C=C1O LBQIJVLKGVZRIW-UHFFFAOYSA-N 0.000 claims description 2
- 229940065115 grapefruit extract Drugs 0.000 claims description 2
- 230000003020 moisturizing effect Effects 0.000 claims description 2
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 claims description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 2
- 230000003658 preventing hair loss Effects 0.000 claims description 2
- 230000002087 whitening effect Effects 0.000 claims description 2
- 229940087126 wild yam extract Drugs 0.000 claims description 2
- 210000002268 wool Anatomy 0.000 claims description 2
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims 4
- 229920006395 saturated elastomer Polymers 0.000 claims 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims 2
- 229930003268 Vitamin C Natural products 0.000 claims 2
- 235000019154 vitamin C Nutrition 0.000 claims 2
- 239000011718 vitamin C Substances 0.000 claims 2
- 240000003259 Brassica oleracea var. botrytis Species 0.000 claims 1
- 241000526900 Camellia oleifera Species 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 229960005188 collagen Drugs 0.000 claims 1
- 229940068052 ginkgo biloba extract Drugs 0.000 claims 1
- 235000020686 ginkgo biloba extract Nutrition 0.000 claims 1
- 230000009759 skin aging Effects 0.000 claims 1
- 231100000245 skin permeability Toxicity 0.000 abstract description 9
- 230000000975 bioactive effect Effects 0.000 abstract description 6
- 239000000463 material Substances 0.000 abstract description 3
- 208000017520 skin disease Diseases 0.000 abstract description 2
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 abstract 1
- 239000005445 natural material Substances 0.000 abstract 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 22
- 239000003963 antioxidant agent Substances 0.000 description 18
- 235000006708 antioxidants Nutrition 0.000 description 18
- 230000000052 comparative effect Effects 0.000 description 16
- 239000004615 ingredient Substances 0.000 description 16
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 238000009472 formulation Methods 0.000 description 12
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 11
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 11
- NSOXQYCFHDMMGV-UHFFFAOYSA-N Tetrakis(2-hydroxypropyl)ethylenediamine Chemical compound CC(O)CN(CC(C)O)CCN(CC(C)O)CC(C)O NSOXQYCFHDMMGV-UHFFFAOYSA-N 0.000 description 11
- 125000005250 alkyl acrylate group Chemical group 0.000 description 11
- 239000001768 carboxy methyl cellulose Substances 0.000 description 11
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 11
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 11
- 229920006037 cross link polymer Polymers 0.000 description 11
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 11
- 210000003491 skin Anatomy 0.000 description 11
- 239000008213 purified water Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 9
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 8
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 8
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 8
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 8
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 8
- 235000005493 rutin Nutrition 0.000 description 8
- 229960004555 rutoside Drugs 0.000 description 8
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 210000004379 membrane Anatomy 0.000 description 7
- 150000003904 phospholipids Chemical class 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 229930007845 β-thujaplicin Natural products 0.000 description 7
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 5
- 206010040880 Skin irritation Diseases 0.000 description 5
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 5
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 150000002978 peroxides Chemical class 0.000 description 5
- 231100000475 skin irritation Toxicity 0.000 description 5
- 230000036556 skin irritation Effects 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 150000002515 isoflavone derivatives Chemical class 0.000 description 4
- 229960002378 oftasceine Drugs 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000306 component Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- BOBLSBAZCVBABY-WPWUJOAOSA-N 1,6-diphenylhexatriene Chemical compound C=1C=CC=CC=1\C=C\C=C\C=C\C1=CC=CC=C1 BOBLSBAZCVBABY-WPWUJOAOSA-N 0.000 description 2
- MOMKYJPSVWEWPM-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-1,3-thiazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=CS1 MOMKYJPSVWEWPM-UHFFFAOYSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 2
- 235000000072 L-ascorbyl-6-palmitate Nutrition 0.000 description 2
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002845 discoloration Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 2
- HELHAJAZNSDZJO-OTWIGTIJSA-L disodium;(2s,3s)-2,3-dihydroxybutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](O)[C@H](O)C([O-])=O HELHAJAZNSDZJO-OTWIGTIJSA-L 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 150000004665 fatty acids Chemical group 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 238000003921 particle size analysis Methods 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 235000010352 sodium erythorbate Nutrition 0.000 description 2
- 239000004320 sodium erythorbate Substances 0.000 description 2
- 235000019983 sodium metaphosphate Nutrition 0.000 description 2
- RBWSWDPRDBEWCR-RKJRWTFHSA-N sodium;(2r)-2-[(2r)-3,4-dihydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethanolate Chemical compound [Na+].[O-]C[C@@H](O)[C@H]1OC(=O)C(O)=C1O RBWSWDPRDBEWCR-RKJRWTFHSA-N 0.000 description 2
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- MLIKYFGFHUYZAL-UHFFFAOYSA-K trisodium;hydron;phosphonato phosphate Chemical compound [Na+].[Na+].[Na+].OP([O-])(=O)OP([O-])([O-])=O MLIKYFGFHUYZAL-UHFFFAOYSA-K 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 244000308180 Brassica oleracea var. italica Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241000167550 Centella Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- ATGQXSBKTQANOH-UWVGARPKSA-N N-oleoylphytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(=O)CCCCCCC\C=C/CCCCCCCC ATGQXSBKTQANOH-UWVGARPKSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- VYGQUTWHTHXGQB-UHFFFAOYSA-N Retinol hexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 description 1
- 230000001064 anti-interferon Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229940082487 camellia oleifera seed extract Drugs 0.000 description 1
- 229940044176 ceramide 3 Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229940119217 chamomile extract Drugs 0.000 description 1
- 235000020221 chamomile extract Nutrition 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229940107161 cholesterol Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000008358 core component Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000002875 fluorescence polarization Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000006303 immediate early viral mRNA transcription Effects 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002356 laser light scattering Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- XKLJHFLUAHKGGU-UHFFFAOYSA-N nitrous amide Chemical compound ON=N XKLJHFLUAHKGGU-UHFFFAOYSA-N 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 235000019830 sodium polyphosphate Nutrition 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003700 vitamin C derivatives Chemical class 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B23—MACHINE TOOLS; METAL-WORKING NOT OTHERWISE PROVIDED FOR
- B23D—PLANING; SLOTTING; SHEARING; BROACHING; SAWING; FILING; SCRAPING; LIKE OPERATIONS FOR WORKING METAL BY REMOVING MATERIAL, NOT OTHERWISE PROVIDED FOR
- B23D61/00—Tools for sawing machines or sawing devices; Clamping devices for these tools
- B23D61/02—Circular saw blades
- B23D61/04—Circular saw blades with inserted saw teeth, i.e. the teeth being individually inserted
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B23—MACHINE TOOLS; METAL-WORKING NOT OTHERWISE PROVIDED FOR
- B23D—PLANING; SLOTTING; SHEARING; BROACHING; SAWING; FILING; SCRAPING; LIKE OPERATIONS FOR WORKING METAL BY REMOVING MATERIAL, NOT OTHERWISE PROVIDED FOR
- B23D61/00—Tools for sawing machines or sawing devices; Clamping devices for these tools
- B23D61/02—Circular saw blades
- B23D61/025—Details of saw blade body
Landscapes
- Engineering & Computer Science (AREA)
- Mechanical Engineering (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Abstract
Description
피부를 통한 약물 전달 경로는 경피, 구강 점막, 상피 세포 점막 등 타겟 질병의 위치와 독성 여부 문제에 따라 다양하게 개발이 되어 왔다. 피부 경유 약물 전달 매개체로서 리포좀 시스템이 널리 사용되고 있는데, 일반적으로 리포좀은 여러 종류의 인지질을 핵심 성분으로 막을 형성하며, 수용액상에서는 구형의 구조물을 형성하는데 리포좀 막 내부에 전달 물질이 내포되는 구조를 이루게 된다.Drug delivery routes through the skin have been developed in various ways depending on the location and toxicity of target diseases such as transdermal, oral mucosa, epithelial cell mucosa. The liposome system is widely used as a drug delivery vehicle through the skin. In general, liposomes form membranes with various phospholipids as core components, and spherical structures in aqueous solution form a structure in which a delivery material is contained in the liposome membrane. .
리포좀 막은 극성 머리와 탄화 수소 꼬리로 이루어진 인지질 분자가 내부의수용성 구획과 외부의 수용액 방향으로 극성 머리가 배치된 이중막 구조를 형성한다. 이러한 리포좀의 양극성 성질을 이용하여 리포좀 내부에 특정 물질을 포접시켜줌으로써 리포좀과 피부 각질 세포 간 지질층과의 융화력에 따른 내접된 수용성 생리 활성 물질의 피부 투과능이 촉진되고 따라서 생체 내 타겟 위치까지 약물이 전달될 수 있게 된다.The liposome membrane forms a double membrane structure in which phospholipid molecules consisting of a polar head and a hydrocarbon tail are arranged with a polar head in the direction of an aqueous soluble compartment and an external aqueous solution. By using a bipolar property of the liposomes by encapsulating a specific substance inside the liposomes, the skin permeability of the insoluble water-soluble physiologically active substance according to the compatibility between the liposomes and the lipid layer between the keratinocytes of the skin is promoted, and thus the drug is introduced to the target location in vivo. Can be delivered.
인지질을 계면 활성제로 사용된 리포좀 제형은 피부 각질층 지질의 유동성을 증가시켜 생리 활성 물질의 피부 투과율을 증가시키고[Biochim.Biophys.Acta, 1237(1995) : 176-182] 피부 자극이 적은 장점이 있으나[PSIT Vol.3, No. 12(2000) : 417-425] 인지질만으로 구성된 리포좀은 구조적 불안정성이란 단점을 가지고 있다.Liposomal formulations using phospholipids as surfactants have the advantage of increasing the fluidity of the stratum corneum lipids to increase the skin permeability of bioactive substances [Biochim. Biophys. Acta, 1237 (1995): 176-182]. PSIT Vol. 3, No. 12 (2000): 417-425] Liposomes composed solely of phospholipids have the disadvantage of structural instability.
계면 활성제로 사용되는 인지질에는 대두나 달걀 유래 레시틴이 있는데 불포화 레시틴으로 제조된 리포좀은 지질의 유동성이 좋아 피부 각질 세포 사이의 지질층, 즉 각질 세포 사이의 간극을 쉽게 통과할 수 있지만 리포좀 구조의 경도가 낮아 그 모양이 쉽게 변하고 천연 식물 추출물이 조성물에 함유되거나 외부 산소, 금속 등에 의해 불포화 레시틴의 이중 결합 부위가 쉽게 산화될 수 있으며, 이에 따라 리포좀 구조가 파괴되어 계면 활성력이 급격히 떨어지게 되고 변색, 변취 문제가 발생하게 된다[Biochemistry Vol.42 No.39 (2003) : 11533-11543].Phospholipids used as surfactants include soy or egg-derived lecithin. Liposomes made of unsaturated lecithin have good lipid flowability and can easily pass through the lipid layer between skin keratinocytes, that is, the gap between keratinocytes. Its low shape makes it easy to change its shape, and natural plant extracts can be contained in the composition, or the double bond sites of unsaturated lecithin can be easily oxidized by external oxygen, metals, etc. Problems arise [Biochemistry Vol. 42 No. 39 (2003): 11533-11543].
수화된 포화 레시틴(hydrogenated lecithin)인 경우에는 불포화 레시틴에서 발생하는 인지질 산화가 일어나지 않기 때문에 변색, 변취, 리포좀 제형 불안정성 문제는 없으나, 레시틴의 지방산 사슬 모두가 포화 탄화수소이므로 지방산 사슬의경직도가 높아져 리포좀 제형의 유동성이 떨어지고 이에 따른 피부 투과능과 피부 친화력이 떨어지는 단점이 있다[Biophysics J. Vol.79 No.1 (2000) : 328-339].Hydrated saturated lecithin does not cause discoloration, odor, and liposome formulation instability because phospholipid oxidation does not occur in unsaturated lecithin, but since the fatty acid chains of lecithin are saturated hydrocarbons, the stiffness of the fatty acid chain is increased, thereby liposome formulation Its fluidity is poor and thus skin permeability and skin affinity are inferior [Biophysics J. Vol. 79 No. 1 (2000): 328-339].
이러한 리포좀 구조에 인지질 막 유동성을 부여해 줄 수 있는 물질로서 콜레스테롤, 당단백질, 터핀 계열 화합물에 대한 연구 결과들이 나오고 있는데[J.Control.Rel. 68(2000) : 85-95, Lipids Vol.32 No.7 (1997) : 769-773], 이러한 물질들의 적절한 배합을 통한 리포좀 구조 유연성 확보와 동시에 리포좀 구조 안정성이 확보된다면 다양한 생리 활성 물질 특히 천연 유래 식물성 물질들과 재조합 단백질 등 효능을 위한 피부 투과능과 동시에 유효 성분의 안정성 확보를 동시에 필요로 하는 분야의 산업적 결과물을 만들 수 있을 것으로 전망한다.As a substance that can impart phospholipid membrane fluidity to the liposome structure, studies on cholesterol, glycoprotein, and terpine-based compounds have been published [J. Control. Rel. 68 (2000): 85-95, Lipids Vol. 32 No.7 (1997): 769-773], various bioactive substances, especially natural It is expected to produce industrial results in fields requiring both skin permeability for efficacy such as derived plant materials and recombinant proteins, and at the same time securing stability of active ingredients.
본 발명은 상기한 문제점들을 해소하기 위한 것으로, 레시틴과 세라마이드 기반 리포좀 조성물에 펜타싸이클릭 트리터핀산과 스테롤이 최적 농도로 리포좀 구조에 구배된 조성물을 통해 생리 활성 천연물 성분 포접능을 최적화 시켜 주고, 동시에 생체 저자극 및 피부 투과능이 향상된 조성물을 구현하고자 한다. 아울러 리포좀 제형에 최적화된 항산화 복합 조성물을 통해 레시틴 기반 리포좀 제형의 산화에 따른 변색, 변취 문제를 해결하고자 한다.The present invention is to solve the above problems, the lecithin and ceramide-based liposome composition to optimize the biologically active natural component inclusion capacity through a composition in which the pentacyclic triterpinic acid and sterol gradient to the liposome structure at the optimal concentration, The present invention seeks to realize a composition having improved bio-hypoallergenic and skin permeability. In addition, through the antioxidant complex composition optimized for liposome formulations to solve the discoloration, deodorant problems caused by oxidation of the lecithin-based liposome formulation.
도1은 본 발명에서 따른 나노 리포좀의 전자 현미경으로 관찰된 구조이다.1 is a structure observed by an electron microscope of a nano liposome according to the present invention.
도2는 나노 리포좀 크기에 대한 입도 분석 결과이다.Figure 2 is a particle size analysis of the nano liposome size.
도3은 인터페론 알파가 포접된 나노 리포좀을 이용한 피부 투과 측정 결과이다.Figure 3 is a skin permeation measurement results using nano liposomes embedded with interferon alpha.
도4는 본 발명에 따른 리포좀의 구조 유연성 테스트4 is a structural flexibility test of liposomes according to the present invention
도5은 본 발명에 따른 리포좀의 구조 안정성 테스트5 is a structural stability test of liposomes according to the present invention
이하 본 발명의 구성 및 작용을 실시예를 통해 보다 상세히 기술한다.Hereinafter, the configuration and operation of the present invention will be described in more detail with reference to Examples.
본 발명에 따른 조성물은 리포좀 혼합물, 유화제, 복합 항산화제, 천연 생리 활성 물질 복합체로 구성이 되며, 리포좀 혼합물은 다시 포화 레시틴, 불포화 레시틴, 세라마이드, 펜타싸이클릭 트리터핀산, 스테롤로 구성이 된다.The composition according to the invention consists of a liposome mixture, an emulsifier, a complex antioxidant, a complex of natural bioactive substances, and the liposome mixture again consists of saturated lecithin, unsaturated lecithin, ceramide, pentacyclic triterpinic acid, sterols.
레시틴은 디올레오일 포스파티딜콜린(DOPC), 디스테아로일 포스파티딜콜린(PSPC), 디팔미토일 포스파티딜콜린(DPPC) 등이 사용되고, 펜타싸이클릭 트리터핀산은 우르솔릭산, 우르솔릭산 유도체 및 이성질체 등이다. 사용 가능한 스테롤은 콜레스테롤(cholesterol), 콜레스테릴 아세테이트(cholesteryl acetate), 콜레스테릴 이소스테아레이트(cholesteryl isostearate), 콜레스테릴 마카다미에이트(cholesteryl macadamiate) 등이다.Lecithin is used for dioleoyl phosphatidylcholine (DOPC), distearoyl phosphatidylcholine (PSPC), dipalmitoyl phosphatidylcholine (DPPC), and the like. Pentacyclic triterpinic acid includes ursolic acid, ursolic acid derivatives, and isomers. The sterols that can be used are cholesterol, cholesteryl acetate, cholesteryl isostearate, cholesteryl macadamiate and the like.
필요에 따라서 추가적으로 가해지는 유화제는 고분자 유화제를 사용하는데 알킬기 탄소수가 10-30인 아크릴레이트/알킬아크릴레이트 크로스 폴리머를 사용하고 유화 보조제로는 천연 고분자 화합물인 카르복시메틸셀룰로오스를 사용한다.The emulsifier to be added as needed is a polymer emulsifier, an acrylate / alkyl acrylate cross-polymer having 10-30 alkyl group carbon atoms, and a carboxymethyl cellulose which is a natural polymer compound as an emulsifying aid.
복합 항산화제로는 지용성 항산화 기능의 토코페롤 및 그 유도체, 비타민 C 유도체, 비타민 A 유도체와 L-트립토판을 사용하고 수용성 항산화제로서 소듐 메타포스페이트(Sodium metaphosphate), 소듐 타트레이트(Sodium D-tartrate), 소듐 폴리포스페이트(Sodium polyphosphate), 소듐 싸이트레이트(Sodium citrate), 소듐 하이드로진 피로포스페이트(Sodium hydrogen pyrophosphate), 소듐 글루타메이트(Sodium L-glutamate), 소듐 에리소베이트(Sodium erythorbate)를 사용한다.Complex antioxidants include fat soluble tocopherols and derivatives thereof, vitamin C derivatives, vitamin A derivatives and L-tryptophan.Sodium metaphosphate, sodium d-tartrate, sodium as water-soluble antioxidants Sodium polyphosphate, sodium citrate, sodium hydrogen pyrophosphate, sodium glutamate, sodium erythorbate is used.
천연 생리 활성 물질로는 로즈마리 추출물, 병풀 추출물, 신이화 추출물, 감초 추출물, 황금 추출물, 녹차 추출물, 카모마일 추출물, 버섯 추출물, 콩 추출물, 폴리페놀류, 터핀 계열 물질, 이소플라본류, 파이토에스토로겐, 비타민 류, 기능성 단백질 류에서 선택되어진다.Natural physiologically active substances include rosemary extract, centella extract, xinhua extract, licorice extract, golden extract, green tea extract, chamomile extract, mushroom extract, soybean extract, polyphenols, terpineic substances, isoflavones, phytoestrogens, vitamins, It is selected from the class of functional proteins.
상기 주요 성분들의 혼합 비율은 다음과 같다. 리포좀 구성 성분 중 레시틴과 세라마이드가 차지하는 양은 조성물 총 중량 기준으로 0.2 에서 4.0 중량% 에 달하고 바람직하게는 0.5 에서 3 중량%를 제시한다. 세부적으로 레시틴과 세라마이드의 함량 조성 비율은 0.4:1.5:0.1(불포화 레시틴/포화 레시틴/세라마이드) 중량 %로 한다. 리포좀의 유연성을 가해주는 펜타싸이클릭 트리터핀산과 스테롤 함량은 0.1 에서 1.0 중량%이고 바람직하게는 0.2에서 0.6 중량%가 적절하고, 조성 비율은 1:1(펜타싸이클릭 트리터핀산:스테롤)에서 1:4 중량 %로 한다.The mixing ratio of the main components is as follows. The amounts occupied by lecithin and ceramide in the liposome constituents range from 0.2 to 4.0% by weight and preferably from 0.5 to 3% by weight, based on the total weight of the composition. Specifically, the content composition ratio of lecithin and ceramide is 0.4: 1.5: 0.1 (unsaturated lecithin / saturated lecithin / ceramide) by weight. The pentacyclic triterpenic acid and sterol content that gives the liposome flexibility is 0.1 to 1.0% by weight, preferably 0.2 to 0.6% by weight, and the composition ratio is 1: 1 (pentacyclic triterpinic acid: sterol). It is 1: 4 weight%.
추가적으로 가해지는 고분자 유화제는 실시예에 따라서 0.05에서 0.2 중량 %로 한다. 유상 성분에는 스테아릴 알코올과 세틸 알코올 등의 고급 알코올 류를 0.5에서 10 중량 % 첨가한다. 중화제로는 통상적으로 많이 사용하는 트리에탄올 대신 니트로소아민 생성이 적은 테트라히드록시프로필에틸렌디아민을 실시예에 따라 0.01에서 1 중량 %를 첨가한다.Additional polymeric emulsifiers are added at 0.05 to 0.2% by weight, depending on the embodiment. To the oil phase components, higher alcohols such as stearyl alcohol and cetyl alcohol are added at 0.5 to 10% by weight. As a neutralizing agent, tetrahydroxypropylethylenediamine with less nitrosoamine production is added in an amount of 0.01 to 1 wt% according to the embodiment instead of triethanol which is commonly used.
천연 생리 활성 물질 함유량은 1.0에서 20 중량% 첨가하고 복합 항산화제의 농도는 0.1에서 10 중량%를 사용하게 되고 바람직하게는 0.5에서 5 중량 %를 첨가하게 된다. 복합 항산화제의 상세 조성 비율은 토코페롤 1%, vitamin A palmitate1%, vitamin C palmitate 1%, L-tryptophan 2.4% , Sodium metaphosphate 7.2%, Sodium D-tartrate 9.6%, Sodium polyphosphate 14.1%, Sodium citrate 9.9%, Sodium hydrogen pyrophosphate 13.8%, Sodium L-glutamate 2.5%, Sodium erythorbate 35.9% 이다.The natural bioactive substance content is added from 1.0 to 20% by weight and the concentration of the complex antioxidant is from 0.1 to 10% by weight, preferably from 0.5 to 5% by weight. The specific composition of complex antioxidants was 1% tocopherol, 1% vitamin A palmitate, 1% vitamin C palmitate, 1% L-tryptophan, 7.2% Sodium metaphosphate, 9.6% Sodium D-tartrate, 14.1% Sodium citrate and 9.9% , Sodium hydrogen pyrophosphate 13.8%, Sodium L-glutamate 2.5%, Sodium erythorbate 35.9%.
나노 리포좀 제조 방법은 대두에서 추출된 레시틴 중에서 포스파티틸콜린 함량이 90~95%인 불포화 레시틴(Phospolipon 90G)과 포화 레시틴(Lipoid S100-3)를 각 실시예에 따른 적정 농도로 혼합하고 세라마이드 3, 올레놀릭산(oleanolic acid), 콜레스테롤 마카다미에이트(cholesterol macadamidate) 및 에탄올을 혼합하여 60oC에서 가온 용해 시킨 다음, 70oC로 가열되어 용해되어 있는 수상 성분들을 혼합하여 균질기(homogenizer)로 5,000 rpm에서 10분간 유화한 후, 고압 균질기(Microfluidizer)를 사용하여 1,000 기압에서 5회 상온 재순환 처리한다.Nano liposome manufacturing method is a lecithin extracted from soybeans, unsaturated lecithin (Phospolipon 90G) and saturation lecithin (Lipoid S100-3) having a phosphatitylcholine content of 90 ~ 95% and mixed in the appropriate concentration according to each embodiment and ceramide 3 , Oleanolic acid, cholesterol macadamidate and ethanol are mixed and heated at 60 o C, then heated to 70 o C to mix the dissolved aqueous phase homogenizer. After emulsifying at 5,000 rpm for 10 minutes, a high-temperature homogenizer (Microfluidizer) was used to recirculate 5 times at room temperature at 1,000 atmospheres.
<실시예 1,2,3,4,5,6,7,8,9 및 비교예 1,2> 최적 리포좀 조성물 함량 스크리닝Example 1,2,3,4,5,6,7,8,9 and Comparative Examples 1,2> Optimal Liposome Composition Content Screening
<시험예 1 : 나노 리포좀 물리적 성질 분석>Test Example 1: Analysis of physical properties of nano liposomes
본 발명에 따른 리포좀 구조는 저온에서 리포좀 구조를 고정화 시킨 후 투사 전자 현미경(CEM 902, Germany)을 통해 관찰하였고 그 결과는 표1에 정리를 하였다.The liposome structure according to the present invention was observed through a projection electron microscope (CEM 902, Germany) after fixing the liposome structure at low temperature and the results are summarized in Table 1.
결과에 따르면 본 발명에 따른 리포좀의 평균 크기는 100~200 nm 범위를 갖음을 확인할 수가 있다.According to the results it can be confirmed that the average size of the liposome according to the present invention has a range of 100 ~ 200 nm.
입도 분석기(Laser Light Scattering System)를 통한 나노 리포좀 크기 분포 분석 결과는 도2에 나타나 있고 약 100nm 주변에 분포가 되는 특성을 보여 준다.The results of nano liposome size distribution analysis using a particle light analyzer (Laser Light Scattering System) are shown in FIG. 2 and show characteristics of distribution around 100 nm.
리포좀은 일반적으로 온도가 높아지면 구조의 경도가 커지게 되고 온도가 낮아지면 리포좀 막 유동성이 증가하게 되는데, 이는 리포좀 내 유효 성분의 방출능에 영향을 주게 된다. 본 발명에 따른 리포좀 조성물은 기존 일반적인 리포좀 구조와는 달리 저온이든 고온에서든 리포좀 막의 적정 유동성을 가지게 됨으로써 리포좀 내 유효 성분의 불필요한 방출이나 적정 속도로 방출 속도를 가짐으로써 최적의 생리 활성 전달 구조체 역할을 하게 된다.In general, liposomes have increased structure hardness at higher temperatures and increased fluidity of liposome membranes at lower temperatures, which affects the release of active ingredients in liposomes. Unlike the conventional liposome structure, the liposome composition according to the present invention has a proper fluidity of the liposome membrane at a low temperature or a high temperature, thereby serving as an optimal biologically active delivery structure by having an unnecessary release rate or an appropriate rate of release of the active ingredient in the liposome. do.
구체적인 분석 방법은 형광 표지 물질로서 DPH(1,6-diphenyl-1,3,5-hexatriene)을 리포좀 제조시 첨가하여 형광 전이도(fluorescence polarization : 358nm excitation/430nm emission) 변화를 관찰함으로써 리포좀 구조의 유동성을 평가한다. 그 결과는 도5에 정리하였다.A specific analysis method is the addition of DPH (1,6-diphenyl-1,3,5-hexatriene) as a fluorescent labeling agent in the preparation of liposomes to observe the change in fluorescence polarization (358 nm excitation / 430 nm emission). Evaluate liquidity. The results are summarized in FIG.
<시험예 2 : 나노 리포좀 구조 안정성 테스트><Test Example 2: Nano liposome structure stability test>
본 발명에서 고안된 리포좀 구조 안정성을 테스트하기 위해 리포좀 내에calcein(미국 Biotium 사 판매) 화합물을 포접하여 시간별 리포좀 안에서 방출되는 calcein양을 분석하였다[Liposome Technology 1983]. 제조된 Calcein 함유 리포좀은 42도 항온 상태에서 형광분석기(Perkin-Elmer luminescence spectrophotometer model LS-5 : 482nm excitation, 512nm emission)를 통해 분석하였고 calcein 방출량은 다음과 같은 공식을 적용하였다.In order to test the stability of the liposome structure designed in the present invention, the calcein amount released in the liposome was analyzed by inclusion of a calcein (sold by Biotium, USA) compound in the liposome [Liposome Technology 1983]. The prepared Calcein-containing liposomes were analyzed by a fluorescence spectrometer (Perkin-Elmer luminescence spectrophotometer model LS-5: 482nm excitation, 512nm emission) at 42 ° C.
Calcein leakage(%) = 100 x (F-Fo)/(Ft-Fo)Calcein leakage (%) = 100 x (FF o ) / (F t -F o )
Ft:t시간대 계면 활성제로 리포좀 구조 파괘했을 때 형광 세기F t : t Fluorescence intensity when liposome structure was disturbed with time zone surfactant
Fo:초기 형광 세기F o : Initial fluorescence intensity
F : t시간대 형광 세기F: t-time fluorescence intensity
결과는 도6에 정리가 되었고 비교예 3에 대한 결과에서 알 수 있듯이 약 1시간 가량 후에 80%가량의 방출이 있지만, 본 발명에서 고안된 리포좀 조성물인 실시예 10,11,12,13에 대한 결과는 20% 미만의 안정적인 리포좀 포접능을 보여 준다.The results are summarized in FIG. 6, and as can be seen from the results for Comparative Example 3, there was about 80% of release after about 1 hour, but the results for Examples 10, 11, 12, and 13, which are the liposome compositions designed in the present invention. Shows stable liposome inclusion of less than 20%.
<시험예 3 : 나노 리포좀 제형 안정성 테스트><Test Example 3: Nano liposome formulation stability test>
본 발명에 따른 리포좀의 안정성 테스트를 위해 각 실시예 별 시간에 따른 리포좀 크기 변화를 관찰하였다. 시간에 따라 리포좀 크기는 전반적으로 커지게 되고 크기가 커지면 리포좀 구조 불안정성이 증가되는데, 본 발명에 따른 실시예를통해 리포좀 구조 안정성이 증가됨을 확인할 수가 있다. 그 결과는 표2에 정리되었다.In order to test the stability of liposomes according to the present invention, changes in liposome size with time for each example were observed. The liposome size increases with time and the liposome structure instability increases as the size increases, and it can be seen that the liposome structure stability is increased through the embodiment according to the present invention. The results are summarized in Table 2.
<시험예 4 : 리포좀 제형의 과산화물가 분석>Test Example 4: Peroxide Value Analysis of Liposomal Formulations
레시틴 리포좀 제형의 산화 스트레스에 대한 안정도를 측정하기 위해 과산화물가(peroxide value)를 통해 산패도(酸敗度)를 분석했다. 과산화물가 측정은 통상적인 방법인 요오드 적정법을 이용하였다. 그 결과는 표3과 표4에 나타내었고, 본 발명에 따른 실시예 6,7,8,9,에 첨가된 복합 항산화제에 의해 레시틴 제형이 산화 안정도가 증가함을 알 수 있다.In order to measure the stability against oxidative stress of the lecithin liposome formulation, the acidity was analyzed by the peroxide value. Peroxide value was measured by the usual method of iodine titration. The results are shown in Table 3 and Table 4, it can be seen that the oxidative stability of the lecithin formulation is increased by the complex antioxidant added in Examples 6,7,8,9, according to the present invention.
<시험예 5 : 경피 흡수 테스트>Test Example 5: Percutaneous Absorption Test
본 발명에서 고안된 리포좀 조성물의 경피 흡수능을 평가하기 위해서 tape stripping 방법[Int.J.Pharm. 139(1996) 197-203]을 사용하였고, 구체적인 방법을 기술하자면 약 2mM 에 해당하는 NaFI를 비교예1, 실시예1,2,3,4, 제형에 포접시켜주고 나서 10명의 건강한 성인을 대상으로 팔뚝 상박 부위에 약 30분간 도포한 후, scotch magic 테이프(3M사 판매)로 연속해서 15번 각각 도포 부위에 균일한 압력으로 문지른다. 이렇게 해서 얻어진 각각의 테이프는 5ml 메틴올에 넣어 한시간 가량 방치 후에 5ml borate buffer(pH 9)를 첨가하여 형광을 측정한다(Shimadzu RF-540 spectrophotometer, 25도, 493nm excitation/515nm emission)Tape stripping method [Int. J. Pharm. 139 (1996) 197-203], and the specific method is described in that 10 healthy adults were included after inclusion of NaFI corresponding to about 2 mM in Comparative Example 1, Examples 1, 2, 3, and 4, and formulations. After applying for about 30 minutes to the upper arm forearm, rubbing with scotch magic tape (available from 3M) 15 times in succession to each application site with uniform pressure. Each tape thus obtained was placed in 5 ml methinol for about 1 hour, and then 5 ml borate buffer (pH 9) was added to measure fluorescence (Shimadzu RF-540 spectrophotometer, 25 degrees, 493 nm excitation / 515 nm emission).
결과는 다음 표5에 정리가 되었고 본 발병에 따른 리포좀 제형인 경우에 비교예보다 포접된 NaFI 피부 투과능이 우수한 결과을 확인할 수 있었다.The results are summarized in Table 5 below, and in the case of the liposome formulation according to the present disease, the inclusion of NaFI skin permeability was superior to that of the comparative example.
또 다른 피부 투과능 평가 방법으로 인터페론 알파 단백질을 포접시킨(실시예 5) 리포좀을 무모 마우스(hairless mouse)에 도포한 후, 경피 흡수 정도를 관찰하였고 그 결과는 도3에 나타나 있고, 본 발명에 따른 리포좀 조성물은 고분자 단백질의 피부 투과에도 뛰어나다는 결과를 얻을 수 있었다.Another method for evaluating skin permeability was applied to hairless mice with liposomes embedded with interferon alpha protein (Example 5), and then the degree of transdermal absorption was observed and the results are shown in FIG. The liposome composition according to the present invention was excellent in the skin penetration of the polymer protein.
구체적인 실험 방법을 정리하면 무모 마우스에 실험군(실시예 5)과 대조군(비교예 1)를 0.2ml/cm2가량 도포한 후 24시간 방치한다. 테스트 부위 피부 조직을 절단하여 4% paraformaldehyde로 고정화 시켜 준 후, 인터페론 알파에 대한항체(mouse anti-interferon alpha/FITC-conjugated anti-mouse IgG(Sigma))를 통해 투과된 인터페론을 염색한다.In summary, the experimental group (Example 5) and the control group (Comparative Example 1) 0.2ml / cm to the hairless mouse2After applying Leave for 24 hours. After cutting the tissue at the test site and immobilizing it with 4% paraformaldehyde, the antibody was treated with mouse anti-interferon alpha / FITC-conjugated anti-mouse IgG (Sigma). Permeate interferon permeate.
<시험예 6 : 피부 자극 테스트>Test Example 6: Skin Irritation Test
건강한 성인 남녀 실험자 10명의 팔 하박부에 폐쇄 첩포하여 피부 자극 유무를 판정하였다. 그 결과를 표 4에 나타내었다. 하기 결과에서 알 수 있듯이 본 발병에 따른 리포좀 조성물에 대한 피부 자극은 없는 것으로 나타났다.Closure patch was applied to the lower arm of 10 healthy adult male and female experimenters to determine skin irritation. The results are shown in Table 4. As can be seen from the results below, there was no skin irritation for the liposome composition according to the present onset.
0: 자극 없음 1: 최소 자극 2: 약한 자극(홍반)0: no stimulation 1: minimal stimulation 2: mild stimulation (erythema)
3: 심한 자극(홍반, 부종)3: severe irritation (erythema, edema)
다음 실시예는 본 발명에 따른 산업적으로 이용 가능한 조성물들을 예시한 것이고 이에 한정을 두는 것은 아니다.The following examples illustrate, but are not limited to, the industrially available compositions according to the present invention.
<실시예 15 : 여드름 피부용 조성물 예시><Example 15: Example composition for acne skin>
<실시예 16 : 피부 주름 개선 조성물 예시><Example 16: Skin wrinkle improvement composition example>
<실시예 17 : 피부염 개선 조성물 예시>Example 17 Dermatitis Improvement Composition Example
<실시예 18 : 피부 미백 효능 조성물 예시>Example 18 Example of Skin Whitening Efficacy Composition
<실시예 19 : 항균 보습 효능 조성물 예시><Example 19: Antimicrobial moisturizing efficacy composition example>
<실시예 20 : 탈모 예방 및 양모 효능 조성물 예시>Example 20 Hair Loss Prevention and Wool Efficacy Composition Example
<실시예 21 : 건선 피부 개선 조성물 예시>Example 21 Psoriasis Skin Improvement Composition Example
<실시예 22 : 가슴 탄력 개선 조성물 예시>Example 22 Chest Elasticity Improvement Composition Example
본 발명을 통해 고안된 나노 리포좀 조성물은 생체 친화력과 피부 투과능이 뛰어나고 여러 종류의 생리 활성 기능 천연물에 대한 포접능을 최적화할 수 있는 장점을 가지고 있어서 다양한 피부 질환 개선 및 경피 경유 생리 활성 조성물 개발에 사용될 수 있다.The nano liposome composition devised through the present invention has excellent biocompatibility and skin permeability, and has the advantage of optimizing the inclusion ability for various kinds of physiologically active natural products, and thus can be used for improving various skin diseases and developing transdermal bioactive compositions. have.
Claims (25)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020040016334A KR100603814B1 (en) | 2004-03-11 | 2004-03-11 | Nano liposome composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020040016334A KR100603814B1 (en) | 2004-03-11 | 2004-03-11 | Nano liposome composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20040027829A true KR20040027829A (en) | 2004-04-01 |
| KR100603814B1 KR100603814B1 (en) | 2006-07-25 |
Family
ID=37330192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020040016334A KR100603814B1 (en) | 2004-03-11 | 2004-03-11 | Nano liposome composition |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR100603814B1 (en) |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006014035A1 (en) * | 2004-08-06 | 2006-02-09 | Biospectrum, Inc. | Multiple layered liposome and preparation method thereof |
| KR100670440B1 (en) * | 2006-02-22 | 2007-01-16 | 주식회사 하이넷포쉬에화장품 | The stability technology of using the technology of the liposome including adenosine & oil soluble licorice extract and the components of cosmetics including the liposome and the method of manufacturing the components |
| KR100705981B1 (en) * | 2005-10-12 | 2007-04-10 | 주식회사 리제론 | Compositions comprising human growth hormone for preventing hair loss or stimulating hair sprouting |
| KR100713555B1 (en) | 2004-11-23 | 2007-05-04 | 주식회사 코리아나화장품 | Composition for Protection of Hair comprising Ceramide Stabilized in Nanoliposome as Active Ingredient |
| KR100715311B1 (en) * | 2005-08-24 | 2007-05-07 | 한국콜마 주식회사 | A cosmeticss to promote the transepidermal absorption and stabilize ursolic acid for anti-wrinkle and its manufacturing method thereof |
| KR100737101B1 (en) * | 2006-02-18 | 2007-07-06 | 김재용 | The stability technology of using the technology of the liposome including adenosine which is effective for anti-wrinkle and the components of cosmetics including the liposome and the method of manufacturing the components |
| KR100747502B1 (en) * | 2006-03-23 | 2007-08-08 | (주)더페이스샵코리아 | An anti-irritation complex for skin, and a cosmetic composition containing the same |
| KR100752990B1 (en) * | 2006-08-02 | 2007-08-30 | 주식회사 대웅 | Compositions for preventing or treating skin diseases comprising nanoliposomes and natural extracts |
| KR100904370B1 (en) * | 2007-10-15 | 2009-06-23 | 보령메디앙스 주식회사 | Cosmetic Composition containing Nanoliposomes |
| KR100954095B1 (en) * | 2009-08-17 | 2010-04-23 | 심보미 | Comoposition for prevention and improvement of wrinkle based on physical constitution |
| CN102793665A (en) * | 2011-05-26 | 2012-11-28 | 河南羚锐制药股份有限公司北京药物研究院 | Flexible nanoliposomes with procyanidine and preparation method for flexible nanoliposomes |
| WO2013065416A1 (en) * | 2011-10-31 | 2013-05-10 | 富士フイルム株式会社 | Aqueous dispersion and method for producing same |
| KR101292539B1 (en) * | 2005-09-02 | 2013-08-20 | 오츠카 세이야쿠 가부시키가이샤 | Antitumor agent |
| KR20150116644A (en) | 2014-04-08 | 2015-10-16 | 전라남도 | Oyster larva's seed collecting device |
| KR102531980B1 (en) * | 2022-08-18 | 2023-05-12 | 엘앤피코스메틱(주) | Method for producing centella asiatica extract and cosmetic composition comprising centella asiatica extract obtained thereof |
| EP4021413A4 (en) * | 2019-08-30 | 2023-07-05 | United States Government as Represented by The Department of Veterans Affairs | Liposomal troponoid compound formulations |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100824958B1 (en) * | 2006-12-05 | 2008-04-28 | 주식회사 피코스텍 | Cosmetic composition containing oriental herb extract and nano ceramide |
| KR100834687B1 (en) * | 2007-02-21 | 2008-06-02 | 주식회사 엘지생활건강 | Lipid nano-particle containing hinokitiol and manufacturing method thereof |
| KR101594687B1 (en) | 2014-08-28 | 2016-02-18 | (주)미애부생명과학 | Nature liposome and process for the preparation thereof |
| KR101727974B1 (en) | 2014-11-26 | 2017-04-27 | (주)엠앤씨생명과학 | Natural liposome comprising ceramide, process for the preparation thereof, and cosmetic composition comprising the same |
| KR101779671B1 (en) | 2015-11-11 | 2017-09-19 | (주)엠앤씨생명과학 | Natural riposome comprising saccharomyces genus yeast extract, its preparation process, and food or pharmaceutical composition comprising it |
-
2004
- 2004-03-11 KR KR1020040016334A patent/KR100603814B1/en active IP Right Grant
Cited By (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4758915B2 (en) * | 2004-08-06 | 2011-08-31 | バイオスペクトラム，インコーポレイテッド | Multilamellar liposome and production method thereof |
| WO2006014035A1 (en) * | 2004-08-06 | 2006-02-09 | Biospectrum, Inc. | Multiple layered liposome and preparation method thereof |
| KR100713555B1 (en) | 2004-11-23 | 2007-05-04 | 주식회사 코리아나화장품 | Composition for Protection of Hair comprising Ceramide Stabilized in Nanoliposome as Active Ingredient |
| KR100715311B1 (en) * | 2005-08-24 | 2007-05-07 | 한국콜마 주식회사 | A cosmeticss to promote the transepidermal absorption and stabilize ursolic acid for anti-wrinkle and its manufacturing method thereof |
| KR101292539B1 (en) * | 2005-09-02 | 2013-08-20 | 오츠카 세이야쿠 가부시키가이샤 | Antitumor agent |
| KR100705981B1 (en) * | 2005-10-12 | 2007-04-10 | 주식회사 리제론 | Compositions comprising human growth hormone for preventing hair loss or stimulating hair sprouting |
| US8846611B2 (en) | 2005-10-12 | 2014-09-30 | Regeron, Inc. | Skin conditions using human growth hormone |
| KR100737101B1 (en) * | 2006-02-18 | 2007-07-06 | 김재용 | The stability technology of using the technology of the liposome including adenosine which is effective for anti-wrinkle and the components of cosmetics including the liposome and the method of manufacturing the components |
| KR100670440B1 (en) * | 2006-02-22 | 2007-01-16 | 주식회사 하이넷포쉬에화장품 | The stability technology of using the technology of the liposome including adenosine & oil soluble licorice extract and the components of cosmetics including the liposome and the method of manufacturing the components |
| KR100747502B1 (en) * | 2006-03-23 | 2007-08-08 | (주)더페이스샵코리아 | An anti-irritation complex for skin, and a cosmetic composition containing the same |
| KR100752990B1 (en) * | 2006-08-02 | 2007-08-30 | 주식회사 대웅 | Compositions for preventing or treating skin diseases comprising nanoliposomes and natural extracts |
| KR100904370B1 (en) * | 2007-10-15 | 2009-06-23 | 보령메디앙스 주식회사 | Cosmetic Composition containing Nanoliposomes |
| WO2011021766A2 (en) * | 2009-08-17 | 2011-02-24 | Sim Bo Mi | Composition for preventing and treating different types of wrinkles depending on physical morphology |
| CN102448434A (en) * | 2009-08-17 | 2012-05-09 | 沈宝美 | Composition for preventing and treating different types of wrinkles depending on physical morphology |
| WO2011021766A3 (en) * | 2009-08-17 | 2011-04-21 | Sim Bo Mi | Composition for preventing and treating different types of wrinkles depending on physical morphology |
| KR100954095B1 (en) * | 2009-08-17 | 2010-04-23 | 심보미 | Comoposition for prevention and improvement of wrinkle based on physical constitution |
| CN102793665A (en) * | 2011-05-26 | 2012-11-28 | 河南羚锐制药股份有限公司北京药物研究院 | Flexible nanoliposomes with procyanidine and preparation method for flexible nanoliposomes |
| WO2013065416A1 (en) * | 2011-10-31 | 2013-05-10 | 富士フイルム株式会社 | Aqueous dispersion and method for producing same |
| JP2013116880A (en) * | 2011-10-31 | 2013-06-13 | Fujifilm Corp | Aqueous dispersion product and manufacturing method therefor |
| KR20150116644A (en) | 2014-04-08 | 2015-10-16 | 전라남도 | Oyster larva's seed collecting device |
| EP4021413A4 (en) * | 2019-08-30 | 2023-07-05 | United States Government as Represented by The Department of Veterans Affairs | Liposomal troponoid compound formulations |
| KR102531980B1 (en) * | 2022-08-18 | 2023-05-12 | 엘앤피코스메틱(주) | Method for producing centella asiatica extract and cosmetic composition comprising centella asiatica extract obtained thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| KR100603814B1 (en) | 2006-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100603814B1 (en) | Nano liposome composition | |
| US20200338151A1 (en) | Encapsulated cannabinoid formulations for transdermal delivery | |
| AU778261B2 (en) | Extracts of feverfew (tanacetum parthenium) against inflammatory disorders | |
| CN112891241B (en) | Targeted mitochondrial skin anti-aging nano composition and preparation method and application thereof | |
| US5614215A (en) | Cosmetic composition for the simultaneous treatment of the surface and deep layers of the skin, its use | |
| KR100603237B1 (en) | Agent for preventing and treating skin diseases | |
| KR101199580B1 (en) | Nanoemulsion for topical administration | |
| KR101355216B1 (en) | A facial mask sheet comprising a composition comprising liposomes for accelerating percutaneous absorptionn | |
| US20040105905A1 (en) | Method for the topical treatment and prevention of inflammatory disorders and related conditions using extracts of feverfew (Tanacetum parthenium) | |
| KR101821207B1 (en) | Solubilization cosmetic composition containing oleanolic acid | |
| EP2691090A2 (en) | Tight junctions modulators | |
| ZA200601179B (en) | Cosmetic composition promoting oxygen transport into the skin | |
| EP1609461A1 (en) | Cosmetic compositions comprising a mixture of N-acyl-phosphatidylethanolamines and cosmetic treatments thereof. | |
| US20110081387A1 (en) | Liposomes encapsulating an oxazolidin-2-one compound | |
| KR102004147B1 (en) | Cosmetic composition contaning lioosome idebenone | |
| KR20150011146A (en) | Retinylpalmitate stabilized formulations | |
| KR101072198B1 (en) | Cosmetic composition for skin whitening | |
| AU2016249759A1 (en) | Natural-substance combination containing at least one glycyrrhetinic acid and at least one guggelsterone and use thereof for cosmetic applications | |
| KR101208120B1 (en) | Vitamin complex, preparation methods and cosmetic composition comprising thereof | |
| KR20190102753A (en) | elastic liposome composition for accelerating skin absorption, elastic liposome containing thereof and manufacturing method thereof | |
| JP5756602B2 (en) | Cosmetic base comprising liposome modified with gelatin and / or elastin-constituting polypeptide and skin cosmetic containing the same | |
| Blume | Flexible liposomes for topical applications in cosmetics | |
| KR100614816B1 (en) | A stable nanocapsule compositon and cosmetic composition comprising the same | |
| CN1249678A (en) | Aqueous composition comprising biotin-contg. liposomes | |
| WO2022186343A1 (en) | Topical microparticle capsule preparation and dermatological topical agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| N231 | Notification of change of applicant | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20130705 Year of fee payment: 8 |
|
| FPAY | Annual fee payment |
Payment date: 20140627 Year of fee payment: 9 |
|
| FPAY | Annual fee payment |
Payment date: 20150619 Year of fee payment: 10 |
|
| FPAY | Annual fee payment |
Payment date: 20170706 Year of fee payment: 12 |
|
| FPAY | Annual fee payment |
Payment date: 20180807 Year of fee payment: 13 |
|
| FPAY | Annual fee payment |
Payment date: 20190703 Year of fee payment: 14 |